Home › Activist investors › Ra Capital Management, L.P.
Other large holder. Positions and campaigns from Ra Capital Management, L.P.’s SEC filings. Updated November 20, 2026.
No active campaign by this definition (see How to read this).
| Company | Stake | Source | First disclosed | Last change | Since previous filing | Flags | Stated intent |
|---|---|---|---|---|---|---|---|
| Climb Bio, Inc. | 33.0%23,941,277 shares | Schedule 13D/A, filed Nov 9, 2026 | Nov 17, 2023 | Increased Nov 9, 2026 | 0.00 pts | Increased | Seeks changes or engagement |
| Pepgen Inc. | 30.5%28,742,212 shares | Schedule 13D/A, filed Nov 17, 2026 | Feb 13, 2024 | Increased Nov 17, 2026 | ▲ 1.30 pts | Increased | — |
| Tyra Biosciences, Inc. | 19.9%14,130,492 shares | Schedule 13D/A, filed Sep 17, 2026 | Feb 6, 2024 | Increased Sep 17, 2026 | ▼ 1.30 pts | Increased | Standard Item 4 language |
| Bambusa Therapeutics, Inc. | 14.6%7,429,758 shares | Schedule 13D, filed Nov 6, 2026 | Nov 6, 2026 | — | — | New | Seeks changes or engagement |
| Sionna Therapeutics, Inc. | 14.3%6,476,193 shares | Schedule 13D/A, filed Sep 21, 2026 | Feb 18, 2025 | Decreased Sep 21, 2026 | ▼ 8.30 pts | Decreased | Seeks changes or engagement |
| Corbus Pharmaceuticals Holdings, Inc. | 9.90%1,914,788 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 4, 2026 | Nov 16, 2026 | — | — | New | 13F: none stated |
| Scribe Therapeutics, Inc. | 9.52%1,802,178 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 31, 2026 | Nov 16, 2026 | — | — | New | 13F: none stated |
| Taysha Gene Therapies, Inc. | 9.34%30,435,190 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 11, 2026 | Nov 14, 2023 | Increased Nov 16, 2026 | ▲ 2.11 pts | Increased | 13F: none stated |
| Agenus Inc. | 9.11%4,122,000 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 3, 2026 | Nov 16, 2026 | — | — | New | 13F: none stated |
| Inovio Pharmaceuticals, Inc. | 6.98%7,220,384 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 10, 2026 | Nov 16, 2026 | — | — | New | 13F: none stated |
| C4 Therapeutics, Inc. | 6.24%8,194,779 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 | Feb 16, 2021 | Increased Nov 16, 2026 | ▼ 0.26 pts | Increased | 13F: none stated |
| Sagimet Biosciences Inc. | 5.53%1,800,000 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Mar 31, 2026 | Nov 16, 2026 | — | — | New | 13F: none stated |
| Inhibikase Therapeutics, Inc. | 5.28%6,970,000 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of May 1, 2026 | Nov 16, 2026 | — | — | New | 13F: none stated |
| Capricor Therapeutics, Inc. | 5.18%3,014,183 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 13, 2026 | Feb 17, 2026 | Increased Nov 16, 2026 | ▲ 2.59 pts | Increased | 13F: none stated |
| JATT III Acquisition Corp | 5.08%450,000 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 12, 2026 | Nov 16, 2026 | — | — | New | 13F: none stated |
| Latigo Biotherapeutics, Inc. | 4.20%5,302,933 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Jun 30, 2026 | Nov 16, 2026 | — | — | New | 13F: none stated |
| Damora Therapeutics, Inc. | 3.88%2,399,702 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 2, 2026 | Nov 16, 2026 | — | — | New | 13F: none stated |
| Equillium, Inc. | 3.66%2,317,741 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 7, 2026 | May 15, 2026 | Decreased Nov 16, 2026 | ▼ 1.23 pts | Decreased | 13F: none stated |
| Amylyx Pharmaceuticals Inc. | 3.33%4,279,341 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 26, 2026 | Nov 16, 2026 | — | — | New | 13F: none stated |
| Jade Biosciences, Inc. | 2.89%1,835,542 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 3, 2026 | Aug 16, 2021 | Decreased Nov 16, 2026 | ▼ 2.89 pts | Decreased | 13F: none stated |
| Ovid Therapeutics Inc. | 2.87%5,598,200 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 11, 2026 | Aug 14, 2020 | Decreased Nov 16, 2026 | ▼ 2.51 pts | Decreased | 13F: none stated |
| Entera Bio Ltd. | 2.81%4,901,960 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 2, 2026 | Nov 16, 2026 | — | — | New | 13F: none stated |
| Electra Therapeutics, Inc. | 2.69%1,692,965 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 6, 2026 | Nov 16, 2026 | — | — | New | 13F: none stated |
| Anteris Technologies Global Corp. | 2.54%2,474,076 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 10, 2026 | May 15, 2026 | Decreased Nov 16, 2026 | ▼ 0.54 pts | Decreased | 13F: none stated |
| Cyclerion Therapeutics, Inc. | 1.96%892,743 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 2, 2026 | Nov 16, 2026 | — | — | New | 13F: none stated |
| Sutro Biopharma, Inc. | 1.27%210,934 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 7, 2026 | Nov 16, 2026 | — | — | New | 13F: none stated |
| DBV Technologies | 1.16%3,657,644 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 26, 2026 | Nov 16, 2026 | — | — | New | 13F: none stated |
| Artiva Biotherapeutics, Inc. | 37.9%18,415,956 shares | Schedule 13D/A, filed Jul 23, 2026 | Jul 29, 2024 | Increased Jul 23, 2026 | ▲ 1.30 pts | — | Seeks changes or engagement |
| Acumen Pharmaceuticals, Inc. | 29.5%21,101,669 shares | Schedule 13D/A, filed Mar 17, 2026 | Jul 25, 2023 | Increased Mar 17, 2026 | ▲ 4.70 pts | — | Seeks changes or engagement |
| Acrivon Therapeutics, Inc. | 28.8%12,284,906 shares | Schedule 13D/A, filed Apr 23, 2026 | Apr 11, 2024 | Increased Apr 23, 2026 | ▲ 7.20 pts | — | Standard Item 4 language |
| Spyglass Pharma, Inc. | 24.1%8,022,639 shares | Schedule 13D, filed Feb 17, 2026 | Feb 17, 2026 | — | — | — | Seeks changes or engagement |
| Parabilis Medicines, Inc. | 23.8%28,933,371 shares | Schedule 13D, filed Jun 18, 2026 | Jun 18, 2026 | — | — | — | Seeks changes or engagement |
| Vor Biopharma Inc. | 19.9%12,937,855 shares | Schedule 13D/A, filed Jul 21, 2026 | Aug 11, 2023 | Increased Jul 21, 2026 | 0.00 pts | — | Standard Item 4 language |
| Janux Therapeutics, Inc. | 19.9%11,971,377 shares | Schedule 13D/A, filed Mar 10, 2025 | Mar 6, 2024 | Increased Mar 10, 2025 | ▼ 0.09 pts | — | Standard Item 4 language |
| Nkarta, Inc. | 18.9%13,848,371 shares | Schedule 13D/A, filed Mar 29, 2024 | Mar 29, 2024 | — | — | — | Standard Item 4 language |
| Wave Life Sciences, Inc. | 16.8%34,314,406 shares | Schedule 13D/A, filed Aug 11, 2026 | Oct 1, 2024 | Increased Mar 30, 2026 | ▼ 0.30 pts | — | Standard Item 4 language |
| Hemab Therapeutics Holdings, Inc. | 16.72%7,808,627 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Jul 31, 2026 | Aug 14, 2026 | — | 0.00 pts | — | 13F: none stated |
| Freenome, Inc. | 14.3%15,367,270 shares | Schedule 13D/A, filed Jul 22, 2026 | Dec 12, 2025 | — | ▲ 5.90 pts | — | Seeks changes or engagement |
| Septerna, Inc. | 11.8%5,525,324 shares | Schedule 13D/A, filed Aug 14, 2026 | Nov 4, 2024 | Decreased Aug 14, 2026 | ▼ 4.00 pts | — | Seeks changes or engagement |
| Bicara Therapeutics Inc. | 11.5%7,279,739 shares | Schedule 13D/A, filed Mar 2, 2026 | Sep 23, 2024 | Increased Mar 2, 2026 | ▼ 1.30 pts | — | Seeks changes or engagement |
| Ars Pharmaceuticals, Inc. | 11.1%10,940,977 shares | Schedule 13D/A, filed Oct 1, 2025 | Aug 31, 2023 | Increased Oct 1, 2025 | ▼ 0.20 pts | — | Standard Item 4 language |
| Solid Biosciences Inc. | 10.8%12,036,126 shares | Schedule 13D/A, filed Nov 6, 2026 | Jan 11, 2024 | Increased Jun 24, 2026 | ▼ 1.10 pts | — | Standard Item 4 language |
| Adicet Bio, Inc. | 9.96%932,624 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 3, 2026 | Nov 14, 2022 | — | 0.00 pts | — | 13F: none stated |
| Monopar Therapeutics Inc. | 9.96%667,207 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Apr 30, 2026 | Feb 14, 2025 | — | 0.00 pts | — | 13F: none stated |
| Mineralys Therapeutics, Inc. | 9.9%7,796,433 shares | Schedule 13D/A, filed Sep 8, 2025 | Feb 12, 2024 | Increased Sep 8, 2025 | 0.00 pts | — | Standard Item 4 language |
| SAB Biotherapeutics, Inc. | 9.9%9,609,852 shares | Schedule 13D/A, filed Aug 10, 2026 | Oct 3, 2025 | Increased Aug 10, 2026 | 0.00 pts | — | Standard Item 4 language |
| OnKure Therapeutics, Inc. | 9.87%3,998,333 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 2, 2026 | May 15, 2026 | — | 0.00 pts | — | 13F: none stated |
| Century Therapeutics, Inc. | 9.80%17,754,430 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 3, 2026 | Aug 16, 2021 | — | 0.00 pts | — | 13F: none stated |
| Rezolute, Inc. | 9.77%9,445,039 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Sep 21, 2026 | Feb 17, 2026 | — | ▼ 0.04 pts | — | 13F: none stated |
| 4D Molecular Therapeutics, Inc. | 9.66%5,049,779 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Mar 31, 2026 | Aug 14, 2023 | — | 0.00 pts | — | 13F: none stated |
| Rhythm Pharmaceuticals, Inc. | 9.62%6,666,837 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 2, 2026 | Aug 14, 2018 | — | ▼ 0.07 pts | — | 13F: none stated |
| ALX Oncology Holdings Inc. | 9.41%13,011,849 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Jul 30, 2026 | May 15, 2026 | — | 0.00 pts | — | 13F: none stated |
| Evommune, Inc. | 8.5%3,494,638 shares | Schedule 13D/A, filed Nov 10, 2026 | Nov 17, 2025 | Increased Feb 17, 2026 | ▼ 1.20 pts | — | Seeks changes or engagement |
| NewAmsterdam Pharma Company N.V. | 8.24%9,883,524 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 2, 2026 | Feb 14, 2023 | — | ▼ 0.03 pts | — | 13F: none stated |
| Prelude Therapeutics Incorporated | 8.13%6,475,882 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of May 7, 2026 | Aug 14, 2026 | — | 0.00 pts | — | 13F: none stated |
| Aclaris Therapeutics, Inc. | 8.02%12,723,026 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 | Feb 16, 2016 | — | ▼ 0.62 pts | — | 13F: none stated |
| Q32 Bio Inc. | 7.79%2,332,457 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 31, 2026 | Aug 14, 2026 | — | ▼ 0.04 pts | — | 13F: none stated |
| Edgewise Therapeutics, Inc. | 7.67%8,392,730 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 31, 2026 | May 17, 2021 | — | ▼ 0.06 pts | — | 13F: none stated |
| Vaxcyte, Inc. | 7.25%11,474,599 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 2, 2026 | Aug 14, 2020 | — | ▼ 0.46 pts | — | 13F: none stated |
| Xencor, Inc. | 7.03%5,274,274 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 | May 15, 2014 | — | ▼ 0.06 pts | — | 13F: none stated |
| LB Pharmaceuticals Inc | 6.82%2,208,604 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 3, 2026 | Nov 14, 2025 | — | ▼ 0.02 pts | — | 13F: none stated |
| Sana Biotechnology, Inc. | 6.74%18,750,000 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Apr 30, 2026 | Aug 14, 2026 | — | 0.00 pts | — | 13F: none stated |
| Geron Corporation | 6.64%42,754,145 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 | Aug 14, 2020 | — | ▼ 0.03 pts | — | 13F: none stated |
| JATT II Acquisition Corp. | 6.41%500,000 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 12, 2026 | Aug 14, 2026 | — | ▲ 0.18 pts | — | 13F: none stated |
| Lexeo Therapeutics, Inc. | 6.37%5,000,000 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of May 7, 2026 | May 15, 2024 | — | 0.00 pts | — | 13F: none stated |
| Editas Medicine Inc. | 5.79%8,889,000 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Jul 31, 2026 | Aug 14, 2026 | — | 0.00 pts | — | 13F: none stated |
| Disc Medicine, Inc. | 5.38%2,450,221 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 29, 2026 | May 15, 2025 | — | ▼ 1.00 pts | — | 13F: none stated |
| Benitec Biopharma Inc. | 5.30%1,850,000 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Sep 4, 2026 | Feb 17, 2026 | — | ▼ 0.08 pts | — | 13F: none stated |
| Assembly Biosciences, Inc. | 5.01%1,020,410 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 7, 2026 | Nov 14, 2025 | — | 0.00 pts | — | 13F: none stated |
| Rani Therapeutics Holdings, Inc. | 4.72%8,500,000 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Mar 31, 2026 | Feb 17, 2026 | — | 0.00 pts | — | 13F: none stated |
| Palisade Bio, Inc. | 4.10%7,124,116 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of May 7, 2026 | Feb 17, 2026 | — | 0.00 pts | — | 13F: none stated |
| Palatin Technologies, Inc. | 3.49%62,124 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Sep 25, 2026 | Feb 17, 2026 | — | 0.00 pts | — | 13F: none stated |
| Altimmune Inc. | 3.34%6,500,000 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 7, 2026 | Aug 14, 2026 | — | 0.00 pts | — | 13F: none stated |
| MacroGenics, Inc. | 2.93%1,864,176 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 8, 2026 | May 15, 2014 | — | 0.00 pts | — | 13F: none stated |
| Aura Biosciences, Inc. | 2.41%2,500,000 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 6, 2026 | Aug 14, 2026 | — | 0.00 pts | — | 13F: none stated |
| Oruka Therapeutics, Inc. | 2.35%1,554,597 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Jul 31, 2026 | Aug 14, 2026 | — | 0.00 pts | — | 13F: none stated |
| Avalo Therapeutics, Inc. | 1.73%1,000,000 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 2, 2026 | Nov 14, 2024 | — | ▼ 0.14 pts | — | 13F: none stated |
| Seaport Therapeutics, Inc. | 1.31%700,000 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 27, 2026 | Aug 14, 2026 | — | 0.00 pts | — | 13F: none stated |
Stake: the latest 13D’s percent of the class (the largest single reporting person’s, as filed), or for a 13F the reported shares as a percent of the company’s shares outstanding on the date shown. Since previous filing: the change in percentage points against the investor’s previous 13D on the company, or its previous 13F.
Item 4 of a Schedule 13D (“Purpose of Transaction”) is where the investor states its plans. The label is a plain reading of that text; the excerpt is quoted from the filing.
“Item 4 of the Statement is hereby amended and supplemented as follows: On June 29, 2026 Dr. Breanna Celebi (O'Reilly), an Analyst of RA Capital, was appointed to the Board of Directors of the Issuer as the designee of RA Capital, replacing Dr. Andrew Levin, who resigned from the Board of Directors effective June 29, 2026.”
Item 4 in the Schedule 13D/A filed Nov 9, 2026; this amendment did not restate Item 4, so the text is from the filing of Jul 7, 2026.
“The Reporting Persons acquired the common stock reported herein for investment purposes and not with an intent, purpose or effect of changing control of the Issuer. The Reporting Persons may, from time to time, acquire additional equity securities or debt securities of the Issuer, which debt securities may be convertible or non-convertible, secured or unsecured, and could involve the monetization of potential revenue streams deriving…”
Item 4 in the Schedule 13D filed Nov 6, 2026.
Summary of the filing RA Capital reports a 14.6% post-IPO stake in Bambusa Therapeutics acquired for investment purposes, with a partner continuing to serve as a company director.
Quoted from the filing (item 4): “Dr. Derek DiRocco, a Partner of RA Capital, currently serves as a director of the Issuer and therefore will engage in regular discussions with the Issuer's board of directors and management as part of his duties as a director.” Nov 6, 2026
“The Reporting Persons acquired the Common Stock reported herein for investment purposes and not with an intent, purpose or effect of changing control of the Issuer. Although the Reporting Persons currently have no plan or proposal to acquire any additional Issuer securities or to dispose of any of the Issuer securities reported herein, the Reporting Persons may, from time to time, acquire additional equity securities or debt securities…”
Item 4 in the Schedule 13D/A filed Sep 21, 2026; this amendment did not restate Item 4, so the text is from the filing of Feb 18, 2025.
“The Reporting Persons acquired the Common Stock reported herein for investment purposes and not with an intent, purpose or effect of changing control of the Issuer. Although the Reporting Persons currently have no plan or proposal to acquire any additional Issuer securities or to dispose of any of the Issuer securities reported herein, the Reporting Persons may acquire additional Issuer securities from time to time or dispose of”
Item 4 in the Schedule 13D/A filed Jul 23, 2026; this amendment did not restate Item 4, so the text is from the filing of Jul 29, 2024.
“The Reporting Persons acquired the Common Stock reported herein for investment purposes and not with an intent, purpose or effect of changing control of the Issuer. Although the Reporting Persons currently have no plan or proposal to acquire any additional Issuer securities or to dispose of any of the Issuer securities reported herein, the Reporting Persons may acquire additional Issuer securities from time to time or dispose of…”
Item 4 in the Schedule 13D/A filed Mar 17, 2026; this amendment did not restate Item 4, so the text is from the filing of Jul 25, 2023.
“The Reporting Persons acquired the common stock reported herein for investment purposes and not with an intent, purpose or effect of changing control of the Issuer. Although the Reporting Persons currently have no plan or proposal to acquire any additional Issuer securities or to dispose of any of the Issuer securities reported herein, the Reporting Persons may, from time to time, acquire additional equity securities or debt securities…”
“The Reporting Persons acquired the voting common stock reported herein for investment purposes and not with an intent, purpose or effect of changing control of the Issuer. The Reporting Persons may, from time to time, acquire additional equity securities or debt securities of the Issuer, which debt securities may be convertible or non-convertible, secured or unsecured, and could involve the monetization of potential revenue streams deriving…”
“Item 4 of the Statement is hereby amended and supplemented as follows: Effective July 6, 2026, Andrew Levin resigned from the Board of Directors of the Issuer.”
“Item 4 of the Statement is hereby amended and supplemented as follows: The information in Item 6 is incorporated herein. At 11:59 pm on October 15, 2024, pursuant to the Stock Purchase Agreement, the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired. All closing conditions were satisfied, and the transactions contemplated by the Stock Purchase Agreement…”
Item 4 in the Schedule 13D/A filed Mar 10, 2025; this amendment did not restate Item 4, so the text is from the filing of Oct 22, 2024.
“Item 4 of the Statement is hereby amended and supplemented as follows: On August 7, 2026, as part of the Redomiciliation, Wave-Delaware, became the ultimate parent company of the Wave Life Sciences group of companies. Pursuant to the Scheme of Arrangement, all issued ordinary shares in the capital of Wave Life Sciences Ltd. ("Wave-Singapore") as of immediately prior to the effective time of the Scheme…”
Item 4 in the Schedule 13D/A filed Aug 11, 2026.
Summary of the filing RA Capital's 13D/A reports completion of Wave Life Sciences' Delaware redomiciliation, with Wave-Singapore shares exchanged one-for-one for new Wave-Delaware common stock, and no campaign-specific plans.
Quoted from the filing (item 4): “all issued ordinary shares in the capital of Wave Life Sciences Ltd. ("Wave-Singapore") as of immediately prior to the effective time of the Scheme of Arrangement were exchanged on a one-for-one basis for newly issued shares of common stock” Aug 11, 2026
“The Reporting Persons acquired the common stock reported herein for investment purposes and not with an intent, purpose or effect of changing control of the Issuer. The Reporting Persons may, from time to time, acquire additional equity securities or debt securities of the Issuer, which debt securities may be convertible or non-convertible, secured or unsecured, and could involve the monetization of potential revenue streams deriving…”
“The Reporting Persons acquired the Common Stock reported herein for investment purposes and not with an intent, purpose or effect of changing control of the Issuer. Although the Reporting Persons currently have no plan or proposal to acquire any additional Issuer securities or to dispose of any of the Issuer securities reported herein, the Reporting Persons may, from time to time, acquire additional equity securities or debt securities…”
Item 4 in the Schedule 13D/A filed Aug 14, 2026; this amendment did not restate Item 4, so the text is from the filing of Nov 4, 2024.
“The Reporting Persons acquired the Common Stock reported herein for investment purposes and not with an intent, purpose or effect of changing control of the Issuer. Although the Reporting Persons currently have no plan or proposal to acquire any additional Issuer securities or to dispose of any of the Issuer securities reported herein, the Reporting Persons may, from time to time, acquire additional equity securities or debt securities…”
Item 4 in the Schedule 13D/A filed Mar 2, 2026; this amendment did not restate Item 4, so the text is from the filing of Sep 23, 2024.
“Item 4 is hereby amended and supplemented as follows: On September 29, 2025, the Issuer and certain direct and indirect subsidiaries of the Issuer who may become a party thereto from time to time, as guarantors (the "Guarantors"), and ARS Pharmaceuticals Operations, Inc., a wholly owned subsidiary of the Issuer, as the borrower (the "Borrower" and, collectively with the Guarantors, the "Credit Parties…”
“Item 4 of the Statement is hereby amended and supplemented as follows: Pursuant to the Letter Agreement, RA Capital recommended David Zaccardelli, Pharm.D, and Rita Jain, M.D. to serve as directors of the Issuer. On January 5, 2026, the Board of Directors (the "Board") of the Issuer, following the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Drs. Zaccardelli…”
Item 4 in the Schedule 13D/A filed Aug 10, 2026; this amendment did not restate Item 4, so the text is from the filing of Mar 11, 2026.
“The Reporting Persons acquired the common stock reported herein for investment purposes and not with an intent, purpose or effect of changing control of the Issuer. Although the Reporting Persons currently have no plan or proposal to acquire any additional Issuer securities or to dispose of any of the Issuer securities reported herein, the Reporting Persons may, from time to time, acquire additional equity securities or debt securities…”
Item 4 in the Schedule 13D/A filed Nov 10, 2026; this amendment did not restate Item 4, so the text is from the filing of Nov 17, 2025.
| Company | Last stake | Source | Outcome | Date |
|---|---|---|---|---|
| Biocryst Pharmaceuticals Inc. | 6.19% | 13F, quarter ended Jun 30, 2026filed Aug 14, 2026; % of shares outstanding as of Jul 31, 2026 | Not in the latest 13F | Nov 16, 2026 |
| BioAge Labs, Inc. | 3.64% | 13F, quarter ended Jun 30, 2026filed Aug 14, 2026; % of shares outstanding as of Jul 31, 2026 | Not in the latest 13F | Nov 16, 2026 |
| Definium Therapeutics, Inc. | 1.38% | 13F, quarter ended Jun 30, 2026filed Aug 14, 2026; % of shares outstanding as of Apr 30, 2026 | Not in the latest 13F | Nov 16, 2026 |
| Intellia Therapeutics Inc, | 3.23% | 13F, quarter ended Jun 30, 2026filed Aug 14, 2026; % of shares outstanding as of Jul 31, 2026 | Not in the latest 13F | Nov 16, 2026 |
| Karyopharm Therapeutics Inc. | 8.45% | 13F, quarter ended Jun 30, 2026filed Aug 14, 2026; % of shares outstanding as of Aug 6, 2026 | Not in the latest 13F | Nov 16, 2026 |
| Lenz Therapeutics, Inc. | 0.2% | Schedule 13D/A, filed Nov 2, 2026 | Reported below 5% in a 13D/A | Nov 2, 2026 |
| Werewolf Therapeutics, Inc. | 4.1% | Schedule 13D/A, filed Jul 2, 2026 | Reported below 5% in a 13D/A | Jul 2, 2026 |
| Cidara Therapeutics, Inc. | 0.0% | Schedule 13D/A, filed Jan 9, 2026 | Exited | Jan 9, 2026 |
| 89BIO, Inc. | 0.0% | Schedule 13D/A, filed Nov 3, 2025 | Exited | Nov 3, 2025 |
| Iteos Therapeutics, Inc. | 4.9% | Schedule 13D/A, filed May 19, 2025 | Reported below 5% in a 13D/A | May 19, 2025 |
| Black Diamond Therapeutics, Inc. | 5.0% | Schedule 13D/A, filed May 9, 2024 | Reported below 5% in a 13D/A | May 9, 2024 |
| Connect Biopharma Holdings Ltd | 0.0% | Schedule 13D/A, filed Feb 27, 2024 | Exited | Feb 27, 2024 |
| Icosavax, Inc. | 0.0% | Schedule 13D/A, filed Feb 21, 2024 | Exited | Feb 21, 2024 |
| Cytek Biosciences, Inc. | 5.0% | Schedule 13D/A, filed Sep 19, 2023 | Reported below 5% in a 13D/A | Sep 19, 2023 |
| DICE Therapeutics, Inc. | 0.0% | Schedule 13D/A, filed Aug 9, 2023 | Exited | Aug 9, 2023 |
| Satsuma Pharmaceuticals, Inc. | 0.0% | Schedule 13D/A, filed Jun 12, 2023 | Exited | Jun 12, 2023 |
Filings by other activists on this list (their first 13D or 13F on the company) and by other holders of 5% or more (Schedule 13D or 13G) dated within 180 days of Ra Capital Management, L.P.’s first disclosure in the same company. They are listed together by date only; nothing here says the holders act together.
| Holder | Form | Date | Stake |
|---|---|---|---|
| Orbimed Advisors LLC | Schedule 13D | Jul 29, 2026 | 7.2% |
| ELI LILLY & Co | Schedule 13D | Jul 30, 2026 | 7.3% |
| Avoro Capital Advisors LLC | Schedule 13D | Jul 30, 2026 | 16.4% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Vanguard Capital Management | Schedule 13G | Jul 31, 2026 | 5.0% |
| FMR LLC | Schedule 13G | Aug 6, 2026 | 10.3% |
| RA Capital Management, L.P. | Schedule 13G | Aug 7, 2026 | 9.9% |
| Adage Capital Management, L.P. | Schedule 13G | Aug 12, 2026 | 4.0% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Biotechnology Value Fund L P | Schedule 13D | Aug 4, 2026 | 10.0% |
| Nantahala Capital | 13F | Nov 13, 2026 | 1.7% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Caligan Partners | 13F | Aug 14, 2026 | 8.6% |
| Nantahala Capital | 13F | Nov 13, 2026 | 1.4% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Foresite Capital Fund VI LP | Schedule 13D | Aug 17, 2026 | 14.5% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| JATT Ventures III L.P. | Schedule 13D | Sep 3, 2026 | 22.1% |
| Nantahala Capital | 13F | Nov 13, 2026 | 2.8% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Fairmount Funds Management LLC | Schedule 13D | Sep 11, 2026 | 20.0% |
| Venrock Healthcare Capital Partners III, L.P. | Schedule 13D | Sep 15, 2026 | 9.9% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Orbimed Advisors LLC | Schedule 13D | Sep 25, 2026 | 11.0% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| RTW Investments, LP | Schedule 13G | Feb 17, 2026 | 4.3% |
| Viking Global Investors LP | Schedule 13G | May 15, 2026 | 5.3% |
| Capital World Investors | Schedule 13G | Aug 12, 2026 | 5.6% |
| Venrock Healthcare Capital Partners III, L.P. | Schedule 13G | Aug 14, 2026 | 7.4% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Deep Track Capital, LP | Schedule 13G | Apr 30, 2026 | 10.0% |
| Viking Global Investors LP | Schedule 13G | May 1, 2026 | 6.7% |
| Chen Yu | Schedule 13G | May 1, 2026 | 9.8% |
| RA Capital Management, L.P. | Schedule 13G | May 1, 2026 | 6.5% |
| State Street Corporation | Schedule 13G | May 12, 2026 | 5.5% |
| Tang Capital Management, LLC | Schedule 13G | May 15, 2026 | 0.3% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| ARCH Venture Fund XII, L.P. | Schedule 13D | May 6, 2026 | 11.9% |
| General Atlantic, L.P. | Schedule 13D | May 11, 2026 | 11.5% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| AI Den-Mab LLC | Schedule 13D | May 11, 2026 | 10.4% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Commodore Capital LP | Schedule 13G | Jun 2, 2026 | 9.9% |
| TCG Crossover GP III, LLC | Schedule 13G | Jun 3, 2026 | 9.9% |
| RA Capital Management, L.P. | Schedule 13G | Jun 3, 2026 | 5.8% |
| BlackRock, Inc. | Schedule 13G | Jul 29, 2026 | 5.0% |
| ADAR1 Capital Management, LLC | Schedule 13G | Aug 14, 2026 | 5.8% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Nantahala Capital | 13F | Aug 14, 2026 | 2.9% |
| JATT Ventures II L.P. | Schedule 13D | Sep 15, 2026 | 23.1% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Medtronic plc | Schedule 13D | Jan 29, 2026 | 16.2% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| AI Biotechnology LLC | Schedule 13D | Apr 7, 2026 | 20.0% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Nantahala Capital | 13F | Aug 14, 2026 | 1.1% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| The Vanguard Group | Schedule 13G | Oct 30, 2025 | 4.8% |
| Tang Capital Management, LLC | Schedule 13G | Jan 26, 2026 | 6.6% |
| Highbridge Capital Management, LLC | Schedule 13G | Feb 17, 2026 | 2.3% |
| Suvretta Capital Management, LLC | Schedule 13G | Feb 26, 2026 | 6.6% |
| RA Capital Management, L.P. | Schedule 13G | Aug 3, 2026 | 5.2% |
| State Street Corporation | Schedule 13G | Aug 7, 2026 | 5.9% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Samsara BioCapital, L.P. | Schedule 13D | Oct 30, 2025 | 9.9% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| FMR LLC | Schedule 13G | Jan 8, 2026 | 2.5% |
| The Vanguard Group | Schedule 13G | Jan 30, 2026 | 5.2% |
| Bank of America Corp /De/ | Schedule 13G | Feb 11, 2026 | 6.5% |
| Opaleye Management Inc. | Schedule 13G | May 11, 2026 | 6.6% |
| Balyasny Asset Management L.P. | Schedule 13G | May 15, 2026 | 5.3% |
| Dellora Investments LP | Schedule 13G | Aug 12, 2026 | 5.9% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Vensana Capital I GP, LLC | Schedule 13D | Feb 10, 2026 | 9.9% |
| New Enterprise Associates 17, L.P. | Schedule 13D | Feb 13, 2026 | 22.2% |
| Gilde Healthcare Holding B.V. | Schedule 13D | Feb 13, 2026 | 6.6% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| LSP 7 Cooperatieve U.A. | Schedule 13D | Nov 14, 2025 | 15.7% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Deep Track Biotechnology Master Fund, Ltd. | Schedule 13D | Sep 19, 2025 | 14.9% |
| Pontifax Management 4 G.P. (2015) Ltd. | Schedule 13D | Sep 25, 2025 | 6.3% |
| Nantahala Capital | 13F | Nov 14, 2025 | 3.3% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Wellington Management Group LLP | Schedule 13G | Feb 10, 2025 | 4.7% |
| FMR LLC | Schedule 13G | Feb 12, 2025 | 6.3% |
| Bain Capital Life Sciences Opportunities III, LP | Schedule 13G | Feb 14, 2025 | 3.3% |
| Paradigm BioCapital Advisors LP | Schedule 13G | May 15, 2025 | 3.5% |
| Frazier Life Sciences Public Fund, L.P. | Schedule 13G | Aug 14, 2025 | 3.0% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Orbimed Advisors LLC | Schedule 13D | Feb 13, 2025 | 8.4% |
| Enavate Sciences GP, LLC | Schedule 13D | Feb 18, 2025 | 5.6% |
| Atlas Venture Fund XI, L.P. | Schedule 13D | Feb 18, 2025 | 6.5% |
| TPG GP a, LLC | Schedule 13D | Feb 18, 2025 | 15.2% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Sofinnova Venture Partners XI, L.P. | Schedule 13D | Sep 30, 2024 | 6.7% |
| AH Bio Fund I, L.P. | Schedule 13D | Oct 4, 2024 | 9.0% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| BlackRock, Inc. | Schedule 13G | Feb 5, 2025 | 6.1% |
| Maverick Capital, Ltd. | Schedule 13G | Feb 14, 2025 | 5.4% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| TPG GP a, LLC | Schedule 13D | Sep 18, 2024 | 5.5% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| GC Corp. | Schedule 13D | Jul 29, 2024 | 19.6% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Tang Capital | 13F | May 15, 2024 | 1.4% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Panacea Innovation Ltd | Schedule 13D | Feb 13, 2024 | 16.2% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Forbion Capital Fund IV Cooperatief U.A. | Schedule 13D | Jul 7, 2023 | 10.1% |